Demographic, clinical, and drug treatment profiles of patients with rheumatoid arthritis at eight years (n = 28)
| DAS, disease activity score; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; NSAID, non-steroidal anti-inflammatory drug; PF SF-36, physical function component of the medical outcomes short form 36 item health survey; RF, rheumatoid factor; y, years. | ||
| Female : male (n) | 19 : 9 | |
| Age at 8 year follow up (y) (median (range)) | 55 (39 to 78) | |
| European : Maori : Pacific Islander (n) | 22 : 5 : 1 | |
| Functional assessments (median (range)) | ||
| Sollerman score | 72.5 (64 to 80) | |
| HAQ score | 0.27 (0 to 1.75) | |
| PF SF-36 score | 67.5 (0 to 100) | |
| DAS score | 2.21 (0.58 to 5.47) | |
| Tendon function score | 1 (0 to 17) | |
| Disease activity (median (range)) | ||
| ESR (mm/h) | 26 (2 to 104) | |
| C reactive protein (mg/l) | 5.7 (0.1 to 78.7) | |
| Swollen joint count | 3 (0 to 25) | |
| Tender joint count | 3 (0 to 32) | |
| Drug treatment (n (%)) | ||
| NSAIDs | 15 (54%) | |
| DMARDs | 17 (61%) | |
| hydroxychloroquine | 4 | |
| sulfasalazine | 5 | |
| methotrexate | 10 | |
| leflunomide | 2 | |
| Ever DMARD use | 25 (89%) | |
| Cytotoxic agents | 3 (11%) | |
| Prednisone | 9 (32%) | |
| Steroids | 5 (18%) | |
| Analgesics | 3 (11%) | |